Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disease and is known to be the most common cause of dementia. We previously described the benefits of aromatherapy on the cognitive function of patients with AD utilizing various aromatic essential oils; however, its mechanism of action remains poorly understood. Consequently, in the present study, this mechanism was thoroughly evaluated employing a dementia mice model, specifically the senescence-accelerated mouse prone 8. The mice were exposed to a mixture of lemon and rosemary oil at nighttime as well as to a mixture of lavender and orange oil in the daytime for 2 months. The cognitive function of the mice was assessed before and after treatment with the aromatic essential oils using the Y-maze test. Moreover, the brain levels of amyloid beta (Aβ), abnormally phosphorylated tau, and brain-derived neurotrophic factor (BDNF) were measured following treatment. The benefits of aromatherapy on the cognitive function in mice were confirmed. It was also established that the brain levels of Aβ and abnormally phosphorylated tau were considerably lower in the aromatherapy group, while the levels of BDNF were marginally higher. These results suggest that aromatherapy employing these aromatic essential oils is beneficial for the prevention and treatment of AD.

Highlights

  • Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and is considered to be the most common cause of dementia

  • We examined the benefits of aromatherapy on AD as well as its mechanism of action employing a dementia mice model, namely senescence-accelerated mouse prone 8 (SAMP8)

  • We exposed the mice to a mixture of lemon and rosemary oils at nighttime, and a mixture of lavender and orange oils during the daytime for 2 months

Read more

Summary

Introduction

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and is considered to be the most common cause of dementia. The number of patients with AD continues to increase globally [1]. A number of AD medicines have been approved, the available agents can only temporarily delay symptom progression, and currently, no drugs can cure.

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.